<DOC>
	<DOCNO>NCT01175473</DOCNO>
	<brief_summary>The purpose study compare pharmacodynamic effect lixisenatide ( AVE0010 ) , comparison liraglutide , add-on treatment metformin , period 4 week treatment . The primary objective ass effect lixisenatide , comparison liraglutide , reduce postprandial plasma glucose ( PPG ) assess area plasma glucose concentration curve ( AUC ) standardize breakfast Week 4 . The secondary objective assess effect lixisenatide maximum PPG excursion , change insulin , pro-insulin , C-peptide glucagon plasma concentration follow standardized breakfast , 24-hour profile plasma glucose , glycosylated hemoglobin ( HbA1c ) , satiety marker ( obestatin , peptide YY [ PYY3-36 ] oxyntomodulin ) ; assess clinical laboratory safety profile .</brief_summary>
	<brief_title>Effects Lixisenatide Compared Liraglutide Postprandial Plasma Glucose Patients With Type 2 Diabetes</brief_title>
	<detailed_description>The duration study patient 7 week include screen period 2 week , treatment period 4 week ( Day 1 Day 28 ) , end-of-study visit 7 +/- 2 day last study drug administration .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes mellitus diagnose least 1 year time screen visit , adequately control metformin dose least 1.5 gram per day least 3 month prior screen HbA1c great equal ( &gt; = ) 6.5 % ( recommended American Diabetes Association ) HbA1c le equal ( &lt; = ) 9 % screen Covered Health Insurance System applicable and/or compliance recommendation National ( German ) Law force relate biomedical research Not administrative legal supervision Exclusion criterion : At time screen age &lt; 18 year &gt; =75 year Body Mass Index ( BMI ) : &lt; =20 kilogram per square meter ( kg/m^2 ) &gt; =37 kg/m^2 History metabolic acidosis , include diabetic ketoacidosis within 1 year prior screen Hemoglobinopathy hemolytic anemia History myocardial infarction , stroke , heart failure require hospitalization within 6 month prior time screening , history presence clinically significant diabetic retinopathy , history presence macular edema likely require laser treatment within study period Cardiovascular , hepatic , neurological , endocrine disease , active malignant tumor major systemic disease patient short life expectancy make implementation protocol interpretation study result difficult ( euthyroid patient replacement therapy include dosage thyroxin stable least 3 month prior screen visit ) Uncontrolled inadequately control hypertension time screen rest systolic diastolic blood pressure &gt; 160 millimeter mercury ( mmHg ) &gt; 95 mmHg , respectively Any clinically significant abnormality identify physical examination , laboratory test , vital sign time screen judgment investigator subinvestigator precludes safe completion study Receipt blood plasma product within 3 month prior time screen Investigator subinvestigator , pharmacist , study coordinator , study staff relative thereof directly involve conduct protocol Patients consider investigator subinvestigator inappropriate study reason ( example , impossibility meeting specific protocol requirement schedule visit , unable selfinjections , etc . ) Use oral injectable antidiabetic hypoglycemic agent metformin ( example , alpha glucosidase inhibitor , exenatide , dipeptidyl peptidase IV [ DPPIV ] inhibitor , insulin , thiazolidinedione , sulfonylurea , etc . ) within 3 month prior time screen Use systemic glucocorticoid ( exclude topical application inhale form ) 1 week within 3 month prior time screen Likelihood require treatment screen phase treatment phase drug permit clinical study protocol Use investigational drug within 3 month prior screen Pregnant breastfeed woman woman childbearing potential effective contraceptive method Clinically relevant history gastrointestinal disease associate prolonged nausea vomiting , include , limited , gastroparesis gastroesophageal reflux disease require medical treatment within 6 month prior time screen Any previous treatment lixisenatide liraglutide Allergic reaction glucagon like peptide 1 ( GLP1 ) agonist past ( example , exenatide ) metacresol History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease Personal family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC Known history drug alcohol abuse within 6 month prior time screen Laboratory finding time screening : alanine aminotransferase : &gt; 3 time upper limit normal ( ULN ) laboratory range ; calcitonin &gt; =20 picogram per milliliter ( pg/mL ) ; amylase lipase &gt; 3 time ULN ; total bilirubin &gt; 1.5 time ULN ( except case Gilbert 's syndrome ) ; hemoglobin &lt; 11 gram/deciliter and/or neutrophil &lt; 1500 per cubic millimeter ( mm^3 ) and/or platelet &lt; 100,000/mm^3 ; positive test Hepatitis B surface antigen and/or Hepatitis C antibody Positive reaction test antihuman immunodeficiency virus ( HIV ) type 1 ( HIV1 ) antiHIV2 antibody Renal impairment define creatinine clearance &lt; 60 milliliter per minute ( mL/min ) use CockcroftGault formula</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>